The phase III clinical trial was a multi-center, randomised, double-blind, placebo-controlled study. Dose levels of 100 – 1600mcg were tested in the trial. In the double-blind portion of
Originally scheduled for Wednesday, February 24, 2010, the meeting will be rescheduled due to an administrative delay at the FDA. The FDA informed Theratechnologies that the delay is
Sinobiopharma received SFDA approval for its formulation of Perindopril, the first version of the drug to be developed in China, in April 2009. SFDA regulations require that drug
The Sciclone G3 combines the flexibility of its predecessors with tube-to-plate reformatting technology, non-contact liquid level and clog detection, and advanced blood tube management, in an easy-to-use software
The company said that the drug is designated as a Class III New Medicine with approximately at least four-year market exclusivity protection, upon marketing clearance by the China
The study evaluated the efficacy and safety of Orencia in patients six to 17 years of age with moderate to severe active pJIA, who had an inadequate response
The Phase 1 trial is an open label, multicenter, dose escalation study of Telintra in combination with lenalidomide in patients with non-deletion (5q-) low to intermediate-1 risk MDS.
The company said that the new establishment is an important milestone for its accelerated expansion into global marketplaces. Having explored the Middle East market for five years, Neusoft
Reportedly, on August 3, the two companies announced they entered into the agreement, through which Dow will meet FTC-required divestitures related to its acquisition of Rohm and Haas.
CM-AT is based on research that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein. The inability to digest protein affects the production of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.